Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients
| Autor: | Elisabetta Lecchi, Josh Dillen, Paolo Ferrari, Chiara Silacci-Fregni, Nadine Czudnochowski, Marcel Meury, Tecla Bonora, Valentina Forni-Ogna, Jessica Bassi, Exequiel Dellota, Matteo Mattiolo, Guido Trinci, Laura Pertusini, Christian Saliba, Yves Franzosi, Pietro E. Cippà, Ravindra K. Gupta, Antonio Lanzavecchia, Tatiana Terrot, Giuseppe Bonforte, Olivier Giannini, Mariangela Ventresca, Luca Piccoli, Alberto Badellino, Soraya Lavorato-Hadjeres, Nicola Beria, Davide Corti, Daniela Garzoni, Paolo Hitz, Alessandro Ceschi, Davide Giunzioni, Elisabetta Cameroni, Francesco Muoio, Lorenzo Berwert, Patrick Hernandez |
|---|---|
| Přispěvatelé: | Muoio, Francesco [0000-0003-4963-8665], Ferrari, Paolo [0000-0002-9619-3104], Piccoli, Luca [0000-0002-1085-6502], Apollo - University of Cambridge Repository, University of Zurich, Ito, Etsuro, Hernandez, Patrick, Forni-Ogna, Valentina, Piccoli, Luca, Gupta, Ravindra [0000-0001-9751-1808] |
| Rok vydání: | 2022 |
| Předmět: |
COVID-19 Vaccines
medicine.drug_class Science medicine.medical_treatment Population Antibody Affinity Dose-Response Relationship Immunologic 610 Medicine & health CHO Cells Monoclonal antibody Peritoneal dialysis Cricetulus Neutralization Tests Renal Dialysis Risk Factors medicine Animals Humans Avidity education Neutralizing antibody Dialysis Medicine and health sciences 1000 Multidisciplinary education.field_of_study Multidisciplinary Biology and life sciences biology business.industry SARS-CoV-2 Vaccination Antibodies Neutralizing HEK293 Cells 10199 Clinic for Clinical Pharmacology and Toxicology Case-Control Studies Immunoglobulin G Immunology biology.protein Medicine Hemodialysis mRNA Vaccines Antibody business Research Article Follow-Up Studies |
| Zdroj: | PLoS ONE, Vol 17, Iss 2, p e0263328 (2022) |
| ISSN: | 1932-6203 |
| Popis: | Funder: Swiss Kidney Foundation Patients on dialysis are at risk of severe course of SARS-CoV-2 infection. Understanding the neutralizing activity and coverage of SARS-CoV-2 variants of vaccine-elicited antibodies is required to guide prophylactic and therapeutic COVID-19 interventions in this frail population. By analyzing plasma samples from 130 hemodialysis and 13 peritoneal dialysis patients after two doses of BNT162b2 or mRNA-1273 vaccines, we found that 35% of the patients had low-level or undetectable IgG antibodies to SARS-CoV-2 Spike (S). Neutralizing antibodies against the vaccine-matched SARS-CoV-2 and Delta variant were low or undetectable in 49% and 77% of patients, respectively, and were further reduced against other emerging variants. The fraction of non-responding patients was higher in SARS-CoV-2-na��ve hemodialysis patients immunized with BNT162b2 (66%) than those immunized with mRNA-1273 (23%). The reduced neutralizing activity correlated with low antibody avidity. Patients followed up to 7 months after vaccination showed a rapid decay of the antibody response with an average 21- and 10-fold reduction of neutralizing antibodies to vaccine-matched SARS-CoV-2 and Delta variant, which increased the fraction of non-responders to 84% and 90%, respectively. These data indicate that dialysis patients should be prioritized for additional vaccination boosts. Nevertheless, their antibody response to SARS-CoV-2 must be continuously monitored to adopt the best prophylactic and therapeutic strategy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|